AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Vedanta Biosciences Key Microbiome Patent Upheld in European Opposition Proceedings

May 7, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2019--Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced that the Opposition Division of the European Patent Office has upheld Vedanta’s foundational patent EP2575835 (the “Honda patent”), strengthening Vedanta’s intellectual property position in a key area of microbiome therapeutics. The patent is based on groundbreaking work by Dr. Kenya Honda, a scientific co-founder of Vedanta Biosciences, in identifying bacteria that induce significant immune responses. The upheld patent claims broadly cover compositions of clostridial bacterial species for use in infectious and allergic disease.

Clostridial bacterial species are abundant in the gut and are of high interest for use in the development of live biotherapeutic products designed to colonize and modulate a patient’s microbiome to therapeutic effect. The Honda patent is exclusively licensed to Vedanta under an agreement with the University of Tokyo and provides coverage through at least 2031.

“We welcome this decision which affirms our belief that Dr. Honda’s breakthrough discoveries form the basis for a critical, foundational patent estate for the development and commercialization of human microbiome drugs based on live bacteria,” said Bernat Olle, Ph.D., chief executive officer of Vedanta Biosciences.

The Honda patent, together with additional Vedanta patents, provide the company with a leading IP position in the microbiome field. Vedanta’s patents support the company’s therapeutic candidates for the treatment of autoimmune diseases, such as inflammatory bowel disease (IBD), food allergy, and infectious diseases. Vedanta’s portfolio contains 20 U.S. patents and numerous foreign issuances with coverage extending to 2037.

The Honda patent, EP2575835, was opposed by six parties: Seres Therapeutics Inc., Nestec SA (a subsidiary of Nestlé SA) as well as four anonymous parties. Minor formal claim amendments were entered during the oral proceedings. The patent is now issued in major commercial markets, including the United States, Europe, and Japan.

About Vedanta Biosciences

Vedanta Biosciences  is a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria. Vedanta Biosciences is a leader in the microbiome field with capabilities and deep expertise to discover, develop, and manufacture live bacteria drugs. These include what is believed to be the largest collection of human-gut associated bacteria, a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form. Vedanta Biosciences’ pioneering work, in collaboration with its scientific co-founders, has led to the identification of human commensal bacteria that induce a range of immune responses – including induction of regulatory T cells, CD8+ T cells, and Th17 cells, among others. These advances have been published in leading peer-reviewed journals, including Science ( multiple ), Nature ( 2013,2019 ), Cell, and Nature Immunology. Vedanta Biosciences has harnessed these biological insights and its capabilities to generate a pipeline of programs in infectious disease, autoimmune disease, allergy, and immuno-oncology.

Vedanta Biosciences was founded by PureTech Health (LSE.PRTC). Its scientific co-founders are world-renowned experts in immunology and microbiology who have pioneered the fields of innate immunity, Th17 and regulatory T cell biology, and include Ruslan Medzhitov, Ph.D., (Yale and Howard Hughes Medical Institute (HHMI)), Brett Finlay, Ph.D., (University of British Columbia and HHMI), Kenya Honda, Ph.D., (Keio University and RIKEN), Dan Littman, Ph.D., (New York University and HHMI), Alexander Rudensky, Ph.D., (Sloan Kettering and HHMI), and Jeremiah Faith, Ph.D., (Mount Sinai School of Medicine).

View source version on businesswire.com:https://www.businesswire.com/news/home/20190506005702/en/

CONTACT: Investors

Allison Mead Talbot

+1 617 651 3156

amt@puretechhealth.comU.S. Media

Tom Donovan

+1 857 559 3397

tom@tenbridgecommunications.com

KEYWORD: UNITED STATES EUROPE NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Vedanta Biosciences

Copyright Business Wire 2019.

PUB: 05/07/2019 02:00 AM/DISC: 05/07/2019 02:01 AM

http://www.businesswire.com/news/home/20190506005702/en